Introduction

Survey of Ophthalmology

Volumn 52, Issue 1 SUPPL., 2007, Pages

  Clark, Abbot F ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; ANGIOGENESIS INHIBITOR; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

AGING; ARTICLE; BLINDNESS; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; HUMAN; NONHUMAN; PHOTOACTIVATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT;

EID: 33846250799     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2006.11.007     Document Type: Article

References (10)

1. Clark A.F. Preclinical efficacy of anecortave acetate. Surv Ophthalmol 52 Suppl 1 (2007) S41-S48
2. Clark A.F. Mechanism of action of the angiostatic cortisene anecortave acetate. Surv Ophthalmol 52 Suppl 1 (2007) S26-S34
3. Covert D., Berdeaux G., Mitchell J., et al. Quality of life and health economic assessments of age-related macular degeneration. Surv Ophthalmol 52 Suppl 1 (2007) S20-S25
4. Dahlin D.C., and Rahimy M.H. Pharmacokinetics and metabolism of anecortave acetate in animals and humans. Surv Ophthalmol 52 Suppl 1 (2007) S49-S61
5. Dorrell M., Uusitalo-Jarvinen H., Aguilar E., and Friedlander M. Ocular neovascularization; basic mechanisms and therapeutic advances. Surv Ophthalmol 52 Suppl 1 (2007) S3-S19
6. Heaton J., Kastner P., and Hackett R. preclinical safety of anecortave acetate. Surv Ophthalmol 52 Suppl 1 (2007) S35-S40
7. Kaiser P.K., Goldberg M.F., Davis A.A., et al. Posterior juxtascleral depot administration of anecortave acetate. Surv Ophthalmol 52 Suppl 1 (2007) S62-S69
8. Regillo C.D., D'Amico D.J., Mieler W.F., et al. Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration. Surv Ophthalmol 52 Suppl 1 (2007) S70-S78
9. Russell S.R., Hudson H.L., Jerdan J.A., et al. Anecortave acetate for the treatment of exudative age-related macular degeneration-a review of clinical outcomes. Surv Ophthalmol 52 Suppl 1 (2007) S79-S90
10. Slakter J.S., Carvalho C., Coleman H., et al. The Digital Angiography Reading Center (DARC) role in the anecortave acetate clinical trials. Surv Ophthalmol 52 Suppl 1 (2007) S91-S98